中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.021 seconds)

    T CELL RECEPTORS AND METHODS OF USE THEREOF
    1.
    发明申请
    T CELL RECEPTORS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019471A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057171

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

    IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63 ,  C12N5/0783

    Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

    T CELL RECEPTORS AND METHODS OF USE THEREOF
    2.
    发明申请
    T CELL RECEPTORS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019477A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057177

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

    IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63

    Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MAGE-A2 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

    MHC CLASS II MOLECULES AND METHODS OF USE THEREOF
    4.
    发明申请
    MHC CLASS II MOLECULES AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019474A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057174

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  GUO, Tingxi

    IPC: C07K14/74 ,  A61K38/17 ,  A61P31/00 ,  A61P35/00 ,  C12N15/12

    Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

    MHC CLASS II MOLECULES AND METHODS OF USE THEREOF
    5.
    发明申请
    MHC CLASS II MOLECULES AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019473A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057173

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji

    IPC: C07K14/74 ,  A61K38/17 ,  A61P35/00 ,  C12N15/12 ,  G01N33/567 ,  C12N5/07

    Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

    T CELL RECEPTORS AND METHODS OF USE THEREOF
    6.
    发明申请
    T CELL RECEPTORS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019472A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057172

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

    IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725

    Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

Patent Agency Ranking